William Ross does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...
These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir. ARTISTRY-1 is a phase 2, randomized, multicenter study that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results